New York Approves Castle Biosciences' AdvanceAD-Tx Test for Eczema Treatment

Castle Biosciences announced it has received assay approval from the New York State Department of Health (NYSDOH) for its AdvanceAD-Tx test. This non-invasive gene expression profile test is designed to guide the selection of systemic therapy for patients aged 12 and older suffering from moderate-to-severe atopic dermatitis (AD).

The approval allows for wider access to Castle's precision medicine test in New York, a state with a unique regulatory process for laboratory-developed tests. The company stated this approval demonstrates the quality and rigor applied to its test offerings.

AdvanceAD-Tx analyzes a patient's disease biology from a skin scraping sample, classifying individuals into either a JAK Inhibitor Responder Profile or a Th2 Molecular Profile. This molecular insight aims to help clinicians make more informed and personalized systemic treatment decisions from the outset.

Atopic dermatitis management can be challenging, with patients often experiencing inadequate response to initial therapies. The AdvanceAD-Tx test seeks to address this by providing objective data to personalize treatment strategies, potentially leading to faster symptom relief and improved patient outcomes.